Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19-Reference-Cited by-同舟云学术

Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19

Published:2021-05 Issue:5 Volume:53 Page:525-533
ISSN:1590-8658
Container-title:Digestive and Liver Disease
language:en
Short-container-title:Digestive and Liver Disease

Author:

Campos-Murguía Alejandro,Román-Calleja Berenice Monserrat,Toledo-Coronado Israel Vicente,González-Regueiro José Alberto,Solís-Ortega Alberto Adrián,Kúsulas-Delint Deyanira,Cruz-Contreras Mariana,Cruz-Yedra Nabila,Cubero Francisco Javier,Nevzorova Yulia Alexandrowna,Martínez-Cabrera Carlos Fernando,Moreno-Guillén Paulina,Lozano-Cruz Oscar Arturo,Chapa-Ibargüengoitia Mónica,Gulías-Herrero Alfonso,Aguilar-Salinas Carlos Alberto,Ruiz-Margáin Astrid,Macías-Rodríguez Ricardo Ulises

Funder

Deutsche Forschungsgemeinschaft

European Cooperation in Science and Technology

Ministerio de Economía y Competitividad

ERAB: The European Foundation for Alcohol Research

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference28 articles.

1. COVID-19 Map. Johns Hopkins Coronavirus Resour Cent,2020

2. Predictors of mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis;Tian;J Med Virol,2020